N G Industries (530897)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• Book value of ₹136.38 and P/B of 1.21 provide some asset support, though not a deep discount.
• ROCE of 23.65% shows decent operating capital efficiency if it can be sustained.
• Sales growth of 7.25% and quarterly sales of ₹4 Cr indicate a continuing, albeit small, healthcare services revenue stream.
• Dividend yield of 2.35% offers some cash return while earnings are depressed.

Concerns

• Net profit of ₹0 Cr in the latest quarter and profit growth of -93.74% mean current earnings power is absent.
• ROE of -3.33% conflicts with the positive ROCE; equity holders are not earning a return.
• Piotroski F-Score of 4/9 suggests weak financial health.
• Debt/equity is not available, so leverage risk cannot be judged; the stock is also near the top of its 52-week range despite deteriorating fundamentals.

AI Analysis

Let me start with what I always ask: what am I actually buying? Here I am being asked to pay ₹165.30 for a share with book value of ₹136.38, in a healthcare services business whose latest quarter net profit is ₹0 Cr and whose profit growth has collapsed by 93.74%. That is not an earnings story; it is an asset story. The 1.21 P/B ratio is not a deep discount, and the 2.35% dividend yield is modest compensation while I wait. The positive figure is ROCE of 23.65%, which suggests the operating capital is being put to work efficiently. But I cannot ignore ROE of -3.33%. If equity is not earning a positive return, the operating efficiency is being lost somewhere—non-operating items, taxes, or expenses. Until I see that gap close, I treat the numbers with suspicion. Sales grew 7.25%, but quarterly sales of ₹4 Cr means this is a very small player. There is no obvious moat, and the Piotroski F-Score of 4 out of 9 signals weak financial health. Debt/equity is not disclosed, which bothers me; I cannot judge the leverage risk. A dividend is nice, but dividends are paid out of cash flow, and current profits are zero. A 52-week range up to ₹165.30 tells me the market has been enthusiastic, but Mr. Market's enthusiasm is not the same as intrinsic value. I need evidence of earnings recovery and a return on equity that justifies the price. At this price, I do not have a margin of safety. I would keep it on a watch list: if it gets cheaper relative to book value, or if profits return convincingly, the asset play becomes more interesting. Until then, I pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer